Fused Tricyclic imidazole derivatives as modulators of TNF activity

US9890174B2 · kind B2 · utility

Assignee

• UCB BIOPHARMA SRL · BE

Inventors

• Rikki Peter Alexander · Slough, GB
• Julien Alistair Brown · Slough, GB
• Michael Deligny · Brussels, BE
• Jag Paul Heer · Brussels, BE
• Victoria Elizabeth Jackson · Slough, GB
• Sophie Jadot · Brussels, BE
• Boris Kroeplien · Slough, GB
• Malcolm Mac Coss · Seabrook Island, US
• Yogesh Anil Sabnis · Sandwich, GB
• Dominique Swinnen · Braine-l'Alleud, BE
• Nathalie Van Houtvin · Brussels, BE
• Zhaoning Zhu · Plainsboro, US

Key dates

• Filing date: Dec 8, 2014
• Grant date: Feb 13, 2018
• Expiry date: Dec 8, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D491/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4′,3′:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c′]dipyridine, dihydro-1H-pyrano[3′,4′:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.